ThermoGenesis Announces New Cord Blood Products Distribution Agreements; Biogen Data Shows Potential for BG-12 as an MS Treatment Print E-mail
By Staff and Wire Reports   
Wednesday, 19 September 2012 19:13
Below is a look at some of the headlines for companies that made news in the healthcare sector on September 19, 2012.

ThermoGenesis Corp. (NASDAQ:KOOL)
, a leading supplier of enabling technologies for the processing, storage and administration of cell therapies, said it has signed two additional new channel partner agreements as part of its continuing program to enhance its distribution, technical service and clinical support initiatives of its cord blood products.

Under a new agreement with HVD Biotech Vertriebs GmbH ("HVD"), HVD will have exclusive distribution rights for the AXP® AutoXpress® System and BioArchive® System in 10 European countriesincluding Germany, Austria, and the Czech Republicand 13 Middle Eastern countries, including Egypt, Saudi Arabia and the United Arab Emirates.

The Company also announced an expanded distribution agreement with Comércio Exportação e Importação de Materiais Médicos Ltda ("CEI"), under which CEI will have exclusive distribution rights for the AXP and BioArchive in nine Latin American countries, including Mexico, Brazil, and Argentina. CEI has been distributing the BioArchive System and ThermoGenesis manual cord blood processing and storage sets for cryopreservation of 25mL concentrated samples in Latin American countries since 2000.

"These new integrated agreements, combined with our recently announced distribution agreement in other European markets with Concessus are important milestones in our strategy to provide a customer-centric focus that incorporates sales, service and support for our cord blood product portfolio. We believe these new partners will further both our existing customer relationships and market expansion efforts for our best-in-class offerings," said Hal Baker, Vice President of Commercial Operations for ThermoGenesis.

"We look forward to working with ThermoGenesis on further developing these important European and Middle Eastern markets. We believe there are significant opportunities with cord blood banks in these regions and that ThermoGenesis' offerings provide important competitive advantages," said Hermanus van Duyne, Managing Director of HVD.

"We have had a very positive experience with ThermoGenesis over the past 12 years and are excited about the new market opportunities under our expanded relationship with the Company," said Paulo Pacheco, Chief Executive Officer of CEI.

"These three new distribution agreements spanning three continents should provide us important leverage in these international markets as we seek to facilitate adoption of automation in the cord blood market and expand our footprint outside of the U.S.," said Matthew Plavan, Chief Executive Officer of ThermoGenesis.


=====


Today Biogen Idec (NASDAQ: BIIB)
announced detailed results from its two pivotal clinical trials evaluating oral BG-12 (dimethyl fumarate) for the treatment of multiple sclerosis (MS) were published in the Sept. 20, 2012 issue of The New England Journal of Medicine (NEJM).

Data from the Phase 3 DEFINE and CONFIRM studies show that dimethyl fumarate (240 mg), administered twice daily (BID) or three times daily (TID), demonstrated significant and clinically meaningful reductions in MS relapses and brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS) compared to placebo, as well as showed benefit in slowing the progression of the disease. Dimethyl fumarate is currently under review by regulatory authorities in the United States, European Union, Australia, Canada and Switzerland.

“The publication of both dimethyl fumarate pivotal studies in NEJM is another achievement for this important investigational therapy,” said Katherine Dawson, M.D., senior medical director, Biogen Idec Neurology Research and Development and Biogen Idec lead author on both dimethyl fumarate manuscripts in NEJM. “The data from its clinical development program consistently indicate that dimethyl fumarate may provide tangible benefits and address existing treatment needs of people living with MS. We are working closely with regulatory authorities across the globe with the aim of making the review of dimethyl fumarate as quick as possible.”



Also Wednesday:




Adherex Technologies Inc. (TSX:AHX) (PINKSHEETS:ADHXF)
, a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, announced that the Toronto Stock Exchange (the "TSX") has informed Adherex that it is reviewing the eligibility for continued listing of Adherex's securities on the TSX.

Boston Scientific Corporation (NYSE: BSX)
has signed a definitive agreement to acquire BridgePoint Medical, Inc., a privately held company based in Minneapolis, Minnesota.

Imprimis Pharmaceuticals, Inc. (IMMY:OTCQB)
today announced the initiation of a clinical study of Impracor™, a topical cream that delivers a dose of the pain-relieving, anti-inflammatory drug ketoprofen.

Life Technologies Corporation (NASDAQ: LIFE)
, a world-leading biotechnology company, today announced the completion of a state-of-the-art facility in Beijing where the most advanced DNA testing solutions will be manufactured and readily available to help forensics labs and law enforcement agencies solve crimes more cost effectively in China.

Quidel Corporation (NASDAQ: QDEL)
, a leading provider of diagnostic testing solutions and cellular-based virology assays, announced today that it has received the CE Mark for its Sofia RSV FIA for use on the Sofia Analyzer for the rapid detection of respiratory syncytial virus (RSV).

The Board of Directors of Sigma-Aldrich Corporation (NASDAQ: SIAL) has elected Michael Marberry as a Director of the Company.

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
today announced that Charles P. Hart, Ph.D., Threshold's Vice President of Biology, will present an overview of the company's targeted tumor hypoxia platform at BIOX, Noble Financial Capital Markets' Life Sciences Exposition, to be held at the University of Connecticut, Stamford Campus on September 24-25, 2012.

Tonix Pharmaceuticals Holding Corp. (OTCQB: TNXP)
("TONIX" or the "Company"), a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, today announced the on-line publication of the abstract of preclinical and human pharmacokinetic data related to the Company's fibromyalgia and post-traumatic stress disorder programs that it will present at the 2012 American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals Annual Scientific Meeting to be held from November 10-14, 2012 at the Walter E. Washington Convention Center in Washington, D.C.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter